Skip to main content
Theranexus logo

Theranexus — Investor Relations & Filings

Ticker · ALTHX ISIN · FR0013286259 LEI · 969500BFCV6IC7MFQP20 PA Manufacturing
Open in API
Filings indexed 286 across all filing types
Latest filing 2018-01-17 Capital/Financing Update
Country FR France
Listing PA ALTHX

About Theranexus

https://www.theranexus.com/en/

THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.

Recent filings

Filing Released Lang Actions
BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE - 2ND SEMESTRE 2017
Capital/Financing Update Classification · 99% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE – 2 ND SEMESTRE 2017" (Semi-annual statement of the liquidity contract - 2nd semester 2017). This document details the status of a liquidity contract (a form of market making or share stabilization agreement) held by PORTZAMPARC on behalf of THERANEXUS as of December 31, 2017. This type of regular, periodic report concerning market operations or specific financial arrangements, which is not a full annual report (10-K), earnings release (ER), or interim report (IR), fits best under the general category for specific financial updates or regulatory notices that don't have a dedicated code. Given the options, it is a specific financial/regulatory update. Since it is a report detailing the status of a specific financial arrangement (liquidity contract) and not a general announcement of a report's publication, it is classified as a specific financial filing. It is not a standard quarterly report (IR) or earnings release (ER). It is most closely related to Capital/Financing Update (CAP) as it deals with market stabilization/liquidity provision, or potentially Regulatory Filings (RNS) as a fallback. Given the specific nature of reporting on a liquidity contract, which is a formal arrangement often required by market rules, 'RNS' (Regulatory Filings - general regulatory announcements) is the most appropriate fallback if a more specific code like 'CAP' (Capital/Financing Update) is deemed too broad, although 'CAP' is plausible. However, liquidity contracts are often reported periodically as required by the exchange/regulator. Since it is a formal, periodic report on a specific financial mechanism, and not a general announcement of a report, I will lean towards the most specific applicable category or the general regulatory filing category. Since 'CAP' relates to fundraising/financing structure changes, and this is about market support, 'RNS' serves as the best general regulatory filing category for this specific, non-standard report type.
2018-01-17 French

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.